Home › Funds › Spruce Street Capital LP › LBRX
Spruce Street Capital LP position in LBRX
LB PHARMACEUTICALS INC · Health Care
Spruce Street Capital LP reported holding 1,404,779 shares of LBRX (LB PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$53.9M, representing 8.56% of its reported portfolio and ranking #2 among its reported holdings. Spruce Street Capital LP has disclosed LBRX holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How Spruce Street Capital LP's LBRX position evolved
Spruce Street Capital LP first disclosed a stake in LBRX in Q4 2025 at 1,005,593 shares (US$22.4M). The position peaked in Q3 2026 at 1,404,779 shares, worth US$53.9M. Across 4 filings, Spruce Street Capital LP increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 1,404,779 shares valued at US$53.9M — an increase of 28,620 shares quarter over quarter.. Notable position changes include a 37% increase in Q1 2026 (shares rose 32% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 1.01M | $22.38M | New |
| Q1 2026 | 1.38M | $33.64M | Add |
| Q2 2026 | 1.38M | $44.66M | Hold |
| Q3 2026 | 1.40M | $53.86M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About LBRX and 13F data
LBRX (LB PHARMACEUTICALS INC) is a Health Care company. 106 other funds we track also report a position in LBRX — the largest reported positions include Deep Track Capital, LP (US$108.8M), RA CAPITAL MANAGEMENT, L.P. (US$71.7M), Trails Edge Capital Partners, LP (US$49.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding LBRX
- Deep Track Capital, LP 3.35M sh · $108.82M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 2.21M sh · $71.68M · Q2 2026
- Trails Edge Capital Partners, LP 1.52M sh · $49.43M · Q2 2026
- Commodore Capital LP 1.50M sh · $48.68M · Q2 2026
- TCG Crossover Management, LLC 1.45M sh · $46.97M · Q2 2026
- Caligan Partners LP 1.44M sh · $46.67M · Q2 2026
- Nantahala Capital Management, LLC 1.07M sh · $41.23M · Q3 2026
- Vivo Capital, LLC 800.00K sh · $30.70M · Q3 2026
- Nan Fung Group Holdings Ltd 630.66K sh · $24.20M · Q3 2026
- Logos Global Management LP 585.00K sh · $18.99M · Q2 2026
- GREAT POINT PARTNERS LLC 317.22K sh · $10.30M · Q2 2026
- HighVista Strategies LLC 173.80K sh · $6.67M · Q3 2026
More on Spruce Street Capital LP
FAQ
How long has Spruce Street Capital LP held LBRX?
Spruce Street Capital LP has disclosed LBRX holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is Spruce Street Capital LP's current position in LBRX?
As of Q3 2026, Spruce Street Capital LP holds 1.40M shares of LBRX (LB PHARMACEUTICALS INC), valued at $53.86M, representing 8.56% of its reported portfolio and ranking #2.
Has Spruce Street Capital LP been buying or selling LBRX?
In the latest 13F filing (Q3 2026), Spruce Street Capital LP increased its position in LBRX. The position peaked in Q3 2026 at 1.40M shares.
Which other funds hold LBRX?
Other major institutional holders of LBRX include Deep Track Capital, LP, RA CAPITAL MANAGEMENT, L.P., Trails Edge Capital Partners, LP, among 106 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.